RE:Two analysts Looking at some short-term softness in the equipment sales to China. This happens from time to time especially during times of economic slown downs. HTL is moving more of their business to reoccurring revenue from software and services. This stock is a buy anywhere under $1.50. Comes with a nice moat as well. -------------------------------------------------------------------------------------------------------------------------------------------
Revenue up 16% to $15.7 million and Adjusted EBITDA up 3% to $2.2 million for the quarter
BEVERLY, Mass. and TORONTO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today reported audited financial results for the quarter and nine months ended September 30, 2023.
Financial Highlights
- Sales increased 16% year over year to $15.7 million for the quarter; sales for the nine-month period increased 17% to $41.8 million; sales increased 12% for the quarter and 16% for the nine-month period on a constant currency basis
- Gross profit increased 18% to $7.7 million for the quarter; increased 21% to $24.7 million for the nine-month period
- Adjusted EBITDA increased 3% to $2.2 million for the quarter and increased 11% to $7.8 million for the nine-month period
- Organic sales growth was approximately 5% for the quarter and 10% for the nine-month period
- Net loss was $785 thousand for the quarter and $1.1 million for the nine-month period, versus net income of $99 thousand and $930 thousand in the prior year periods
- Cash generated from operations was $1.5 for the nine-month period versus $471 thousand in the prior year; total cash on hand at September 30, 2023 was $15.3 million
- After quarter end, the Company completed the acquisition of Gynetics.